MEDA: Prospectus Concerning Meda’s Rights Issue Published

Regulatory News:

Meda: (STO:MEDA-A) (Pink Sheets:MDABY)

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Japan, Hong Kong, New Zealand, South Africa or any other jurisdiction where such distribution of this press release would be subject to legal restrictions

The prospectus concerning Meda AB’s rights issue has been approved and registered by the Swedish Financial Supervisory Authority and is now available on Meda’s website www.meda.se as well as on SEB’s website www.sebgroup.com/prospectuses. The prospectus can also be ordered from Meda by telephone +46-8-630 19 00.

The prospectus will be distributed by mail to Meda’s directly registered shareholders in Sweden.

Danske Bank A/S, Danmark, Sverige Filial, Nordea Bank AB (publ) and SEB Corporate Finance, Skandinaviska Enskilda Banken AB (publ) are acting as financial advisors and Advokatfirman Lindahl KB is acting as legal advisor to Meda in connection with the rights issue.

Meda AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 14 2014, at 08:00 CET.

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 150 countries worldwide and the company is represented by its own organizations in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm. Find out more, visit www.meda.se.

Important information

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in Meda. Any invitation to the persons concerned to subscribe for shares in Meda will only be made through the prospectus referred to in this press release.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish, Danish or English law. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares have or will be registered under the U.S. Securities Act of 1933, as amended, ("Securities Act”) or securities legislation in any state or other jurisdiction in the United States and may not be offered or sold, directly or indirectly, in or into the United States, except pursuant to an available exemption from the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.

This press release may contain forward-looking statements which reflect Meda’s current view on future events and financial and operational development. The words "intend”, "estimate”, "expect”, "may”, "plan”, "anticipate” or similar expressions regarding indications or predictions of future developments or trends and which are not statements based on historical facts constitute forward-looking information. Although Meda believes that these statements are based on reasonable assumptions and expectations, Meda cannot give any assurances that such statements will materialize. Forward-looking statements are in its nature involved with both known and unknown risks and uncertainties, since it is depending on future events and circumstances. Forward-looking statements do not constitute any representations and warranties and the outcome could differ materially from the information set out in the forward-looking statements.

This information was brought to you by Cision http://news.cision.com